Reprogramming strategies are highly promising for the development of future regenerative medicine approaches. Over the past 60 years, from the fi rst nuclear transfer experiment to the description of cell fate conversions by forced expression/inhibition of cell-type specifi c transcrip tion factors (TFs) and/or miRNAs, a great deal of evidence showing cell identity switches has been accumulated [1] . Numerous cocktails of TFs have to date been identifi ed for the conversion of somatic cells all the way back to pluripotency or into more specialized cell types. Accordingly, the emergence of cell fate conversion strategies represents a new unexpected source for
generating any desired cell type that could be of interest for the clinic. Th ese lineage conversion strategies could be divided into: direct con version approaches, in which tissue-specifi c TFs are employed and characterized by the lack of proliferation and/or progenitor generation; and indirect conversion approaches, based on the use of so-called pluripotency factors. Indirect lineage conversion, as opposed to direct conversion, is driven by a partial dediff erentiation step, with potential for the generation of expandable pro genitor populations, followed by rediff erentiation into specifi c populations (for a recent review see [1] ).
Noticeably, cerebral tissue has always been one of the most studied tissues for the development of cell-based therapies, sustained by the hope that cell transplantations could facilitate the replacement of lost neural tissue and/ or protect from neurodegenerative processes. Although several cell types have demonstrated encouraging results in animal models, neural stem cells and their derivatives are naturally seen as the most suitable cellular products. Taking into account that access to such cellular material is technically and ethically diffi cult, the advent of lineage conversion strategies has opened new vistas towards the generation of neural cells as well as towards the exploration of new treatment avenues.
In 2010 the Wernig laboratory was the fi rst to meet this challenge by defi ning a set of three TFs -that is, Ascl1, Brn2 and Myt1l -allowing for the generation of functional neurons upon overexpression in mouse fi broblasts [2] . Later on, the same group demonstrated that addition of NeuroD1 to this cocktail was suffi cient to achieve the same conversion in human fi broblasts [3] . Numerous reports have since then reproduced and extended this discovery by identifying other lineage specifi ers able to convert fi broblasts into neural progenitors or more specialized neurons such as motoneurons [4] and dopaminergic neurons [5] . Alternatively, by combining pluripotency-associated reprogramming factors with neural specifi ers or defi ned media, other laboratories have reported that it is feasible to convert fi broblasts into expandable neural stem cells [6] .
From these and other reports, two main lineage conversion strategies can be envisaged for clinical
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applications: the generation of the desired cell type(s) in vitro and its further transplantation; and the local in vivo conversion of one cell type into the one(s) required, in a similar way to what has been experimentally done with pancreatic cells. As a common denominator for most of these studies, however, fi broblasts represent the starting cell type of choice for achieving this lineage conversion; cord blood cells [7] and astrocytes [8] are exceptions to this rule. Th e latest strategy might thus not be the most appropriate unless other cell types present in the brain, and not as essential for brain functions as neural cells, could be reprogrammed.
Interestingly, a recent report from the Berninger laboratory convincingly extended the spectrum of somatic cell types able to give rise to neurons upon forced expression of TFs [9] . In their report, Karow and colleagues describe the in vitro conversion of pericytes, residing in the adult human brain, using only two TFs: Sox2 and Mash1 (Ascl1). Th e authors showed that the so-called human pericyte-derived induced neurons acquired molecular marks and electrophysiological properties resembling those of primary mature neurons, with further maturation when co-cultured with murine neurons. Even though the fi nal evidence for the phenotypic identity of the newly generated neurons is not yet provided, they seem to display the hallmarks of GABAergic interneurons. Of note, the authors observed a conversion rate of about 20% but also an important cell death (≈30%) in the cotransfected cells. Although the mechanism of action controlling this lineage conversion is not fully identifi ed, Sox2 being a pluripotent factor as well as a neural lineage specifi er, a synergic eff ect may occur consisting of Sox2induced partial dediff erentiation alongside activating a neuronal program with both Sox2 and Mash1. Of importance, the authors showed that converted cells do not undergo cell division during this process, supporting the idea that this occurs via a direct conversion mechanism.
In conclusion, pericytes not only represent a new cell type suitable for neuronal conversion but also provide a new cell candidate for in vivo approaches. Indeed, similarly to astrocytes, pericytes have been identi fi ed as one of the core components of post-injury scarifi cation in the central nervous system [10] . Consider ing that peri cytes are amenable to being converted into neurons, we can imagine that these cells, localized within or close to an injured area, may be a good target for in vivo conversion without much eff ect on the surrounding neural cells. However, it will be important to specifi cally convert pericytes in vivo but also to limit the cell death associated with this process. Th e role of resident pericytes after injury should also be precisely studied to avoid any side eff ect upon conversion. Importantly, both central nervous system injuries and neurodegenerative processes generally aff ect more than one cell type, implying that several specialized cells counteracting the eff ects observed in the diseased brain might be needed.
All in all, the study by Karow and colleagues presents pericytes as a new contender in the race to the operating room but we have a long way to go before a particular cell type gets elected. Abbreviations miRNA, microRNA; TF, transcription factor.
